Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
High mobility group box 1 pseudogene 7 (HMGB1P7) is a processed pseudogene that does not code for a protein. Unlike the parental high mobility group box 1 protein (HMGB1), which has nuclear, cytoplasmic, and extracellular functions as a DNA-binding protein and damage-associated molecular pattern (DAMP), HMGB1P7 exerts indirect biological effects by acting as a competing endogenous RNA. It is reported to sequester miRNAs that would otherwise target HMGB1 mRNA, thereby upregulating HMGB1 expression. Such ceRNA activity has been implicated in the development and progression of some cancers, including breast and endometrial carcinoma, through modulation of cell proliferation and tumorigenesis. HMGB1P7 is not considered a conventional molecular target such as a receptor or enzyme, and there are no drugs that specifically target this pseudogene.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on High mobility group box 1 pseudogene 7 (HMGB1P7).